Sjögren's disease is a systemic autoimmune disorder that often causes sicca symptoms – or dryness of the eyes and mouth, alongside many other complications such as fatigue, pain, and neurological manifestations. There are treatments that help with symptoms, but none that address the underlying disease processes.3 One key issue in developing new treatments is that Sjögren's can differ from person to person – and that makes it hard to measure and compare outcomes in a clinical trial.
NECESSITY is an interventional trial looking at new clinical endpoints in Sjögren's disease. This is an international project involving eight European countries, and coordinated by Professor Xavier Mariette. The aim is to identify sensitive endpoints that could be used in clinical trials to assess the efficacy of new medicines. In addition, the project hopes to find biological markers that could be used to identify specific subgroups of people with different disease types.3 Unusually, the project has gathered a consortium of 25 partners across academia and industry – including representatives from patient associations. This is a challenging initiative, but one which could add value and highlight patients' unique experience and expertise around Sjögren's and its numerous unmet needs. To assess the merits of working with patient advisory groups in this way, a survey was sent to each of the other partners. The intention was to collect a scientific point of view, as well as to identify obstacles and areas for improvement.
The main challenges identified included differences in perspectives and perceptions of Sjögren's disease, as well as the need to go beyond strictly scientific considerations in order to include patient opinions and implement their ideas. Another concern was to ensure that patients find their place within the consortium amongst scientists, and about the time sometimes needed to explain technical aspects to ensure effective collaboration. Addressing these challenges will be important for future projects.
But when looking at the benefits of working with patient partners, there were some noteworthy findings. For example, a majority of respondents favoured working with patients to validate unmet needs – especially those around symptoms and care expectations. Some people also expressed the view that patient partners provide moral support, boost motivation, and retain empathy within the consortium. Over 95% of respondents stated they would be willing to seek out patient partners in the future, and view them as genuine research partners.
Overall, the NECESSITY consortium appears to have been a success, and could provide the basis for a collaborative model to address clinical research in the future, helping to answer questions from the perspective of both the patient and the medical community.
Source
Bouillot C, Piatrova A. Myths vs Realities: An honest feedback from the scientific community on collaboration with patients partners in the NECESSITY research project. Presented at EULAR 2024; OP0286-PARE.
Ann Rheum Dis 2024; DOI: 10.1136/annrheumdis-2024-eular.2931.
References
1. Patient Research Partners (PRP). https://www.eular.org/pare-patient-research-partners
2. de Wit MPT, et al. European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. Ann Rheum Dis 2011;70(5):722–26.
3. NECESSITY Project. https://www.necessity-h2020.eu/#necessity-project
About EULAR
EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.
